New Directions in Depression Treatment: Hopes, Challenges, and the Future of Integrated Psychiatry

[1]Zuzanna Czuba, [2]Martin Dahl✉.

[1]Medical University of Warsaw, Poland

[2]Tarnow Academy of Applied Sciences, Poland

Email: augwaw@gmail.com

Abstract

This article presents new directions in the treatment of depression, with particular emphasis on the development of the integrated approach in psychiatry. It discusses contemporary innovations in both psychotherapy and pharmacotherapy, including digital therapy, ketamine-assisted treatment, and the psychotherapeutic use of psychedelics. The article highlights the growing importance of holistic and humanistic approaches—especially Gestalt therapy—and the potential to combine technological advancements with the relational depth of traditional psychotherapy. The aim of the study is to establish a conceptual framework for understanding the future of mental health interventions in the context of increasing social and emotional complexity.

Keywords: *depression treatment, integrated psychiatry, Gestalt therapy, digital therapy, mental health innovation*

Note)Title page containing 2 abstracts and identity must be on the first page,

INTRODUCTION

Depression is currently among the most widespread and urgent mental health challenges worldwide, affecting—according to estimates by the World Health Organization—more than 280 million people (World Health Organization [WHO], 2021). Despite the documented effectiveness of traditional therapeutic methods such as pharmacotherapy and cognitive behavioral therapy (CBT), their efficacy remains limited in cases of treatment-resistant depression and within the context of the increasing psychosocial complexity of contemporary depressive disorders (Cuijpers et al., 2020; Rush et al., 2006). In response to these challenges, recent years have seen a significant expansion of innovative approaches in mental health care, including digital technologies, neurobiologically informed interventions, and holistic therapeutic models aimed at improving the personalization and overall effectiveness of clinical strategies (Insel, 2017).

One of the key paradigms shaping the future of depression treatment is integrated psychiatry. This conceptual model seeks to transcend the dichotomy between biological and psychological frameworks by synthesizing a range of empirically supported methods within a coherent, patient-centered system of care (Kendler, 2012). The goal of integrated psychiatry is not to replace traditional approaches but to enhance them by acknowledging the multifactorial nature of depression—encompassing, in a holistic manner, biological, psychological, social, existential, and environmental components (Engel, 1980; Pincus et al., 2007).

Alongside well-established biological and behavioral models, contemporary research increasingly underscores the importance of relational, somatic, and existential dimensions in both the etiology and treatment of depression. In this context, there is growing interest in approaches that integrate medical innovations, digital technologies, and psychotherapeutic models focused on relational dynamics and personal experience, forming the foundation for further development of modern psychological and psychiatric care systems (Francesetti, 2013; Norcross & Goldfried, 2019).

METHODS

This article adopts a qualitative, conceptual research methodology aimed at identifying and describing key directions in the development of contemporary methods for treating depression, with particular emphasis on the integrated approach. A narrative literature review was employed to provide a selective yet in-depth exploration of the topic based on current scientific knowledge. The analysis included both empirical and review articles published in reputable scientific journals, policy reports from health organizations, and theoretical works in the fields of psychiatry, psychotherapy, and related disciplines, spanning the years 2013–2024.

The literature search was conducted using established academic databases such as PubMed, PsycINFO, and Google Scholar. The selection of sources was preceded by an assessment of their relevance to the research focus, specifically regarding innovative forms of depression treatment, the degree of integration of therapeutic methods in clinical practice, and the effectiveness of humanistic approaches—particularly Gestalt therapy—in the context of affective disorders.

Inclusion criteria encompassed the recency of publications, methodological rigor, representativeness of theoretical orientation, and relevance to the topic of

integration across biological, psychological, and social paradigms. Special attention was given to studies conceptualizing depression as a complex biopsychosocial phenomenon and to those highlighting the need for complementary treatment strategies—combining pharmacotherapy, psychotherapy, digital interventions, and lifestyle-based measures.

RESULTS AND DISCUSSION

Clinical Presentation of Depression

Depression is currently one of the most serious mental health disorders affecting the general population. It frequently impairs functioning in essential areas of life and often leads to the loss of the ability to independently meet basic needs (World Health Organization [WHO], 2021). Contemporary views on the etiology of depression conceptualize it as a complex and multifactorial disorder resulting from the interplay of biological predispositions, psychological experiences, and environmental influences (Kendler, 2012; Cuijpers et al., 2020).

The core clinical feature of depressive disorders is a persistent low mood, accompanied by feelings of sadness, irritability, and emptiness, as well as a loss of the ability to experience pleasure (anhedonia). These symptoms are often accompanied by cognitive, behavioral, and somatic disturbances (American Psychiatric Association [APA], 2013). Self-perception is typically impaired on both emotional and cognitive levels, with frequent occurrences of self-deprecating thoughts, feelings of guilt, worthlessness, and hopelessness.

According to medical classifications—both ICD-10 and the more recent ICD-11—depression is diagnosed as a "depressive episode" (F32) when symptoms occur for the first time, or as "recurrent depressive disorder" (F33) in cases involving repeated episodes, in the absence of manic or hypomanic episodes (World Health Organization, 2019; 2022).

Typical symptoms include low mood, decreased energy and activity, concentration difficulties, sleep and appetite disturbances, low self-esteem, and somatic symptoms such as psychomotor retardation, morning worsening of mood, weight loss, and reduced libido (APA, 2013). Depending on the number and severity of symptoms, a depressive episode may be classified as mild, moderate, or severe. In the most severe cases, psychotic symptoms may also be present.

An untreated episode of depression may last, on average, several months—up to nine months—and more than half of affected individuals experience recurrence (Rush et al., 2006; WHO, 2021). For this reason, it is essential to implement a comprehensive treatment strategy that combines pharmacotherapy, psychotherapy, and psychosocial interventions, which not only shortens the duration of the episode but also significantly reduces the risk of recurrence and supports recovery and quality of life (Cuijpers et al., 2020).

Emerging Trends in Depression Treatment Can Be Grouped Into Five Key Categories:

1. Digital Psychotherapy and Technology-Assisted Interventions

The rapid development of information and communication technologies, along with widespread access to smartphones and the Internet, has created favorable conditions for implementing digital psychotherapeutic interventions in the treatment of depressive disorders. These interventions span a broad spectrum—from mobile applications based on the principles of cognitive behavioral therapy (e.g., Moodpath, Sanvello) to advanced platforms powered by artificial intelligence, such as Woebot and Wysa, which enable interactive, personalized text-based interventions in real time (Fitzpatrick et al., 2017; Inkster et al., 2018).

Empirical studies indicate that digital interventions—particularly those based on CBT—demonstrate comparable effectiveness to traditional therapy in treating mild to moderate depression. A meta-analysis by Carlbring et al. (2018), which included 20 randomized controlled trials, showed that internet-based CBT (iCBT) results in a statistically significant reduction in depressive symptoms compared to control groups receiving standard care or placebo. Similar findings were reported by Andrews et al. (2018), who emphasized that the effectiveness of iCBT increases in guided formats supported by a therapist (guided self-help).

Additional advantages of digital therapy include increased accessibility (especially in rural or remote areas), reduction of stigma associated with psychiatric treatment, time flexibility, and the potential for individualized therapeutic processes. As Mohr et al. (2017) highlight, such solutions can serve as a valuable supplement or alternative to traditional forms of therapy in healthcare systems that are increasingly burdened by rising demand for psychological services.

Despite these advantages, digital therapy also presents certain limitations. Key concerns include difficulties in personalizing interventions, high dropout rates over time, and significant challenges regarding data privacy and security (Baumel et al., 2019).

The rapid advancement of information and communication technologies, along with widespread access to smartphones and the Internet, has created favorable conditions for the implementation of digital psychotherapeutic interventions in the treatment of depressive disorders. These interventions encompass a wide range of solutions—from mobile applications based on cognitive behavioral therapy principles (e.g., *Moodpath*, *Sanvello*) to advanced platforms supported by artificial intelligence, such as *Woebot* and *Wysa*, which enable interactive, personalized, real-time text-based interventions (Fitzpatrick et al., 2017; Inkster et al., 2018).

2. Biological Innovations: Ketamine, Psychedelics, and Novel Compounds

In recent years, there has been growing interest in innovative biological interventions for the treatment of depression, particularly in cases resistant to first-line pharmacological treatments. One of the most significant breakthroughs in this area is the use of ketamine—originally developed as an anesthetic—in subanesthetic doses as a rapidly acting antidepressant. Randomized clinical trials have demonstrated that intravenous ketamine can lead to a substantial reduction in

depressive symptoms within a matter of hours, particularly among patients with treatment-resistant depression (Zarate et al., 2006; Daly et al., 2019).

However, the efficacy of ketamine as an antidepressant must be considered in light of important limitations associated primarily with long-term use, including hepatotoxicity, urological complications, negative effects on cognitive function at high doses, and its addictive potential. Nevertheless, adverse effects observed at therapeutic antidepressant doses are generally well tolerated and transient, typically limited to the period of drug administration (Short et al., 2018).

Further developments in this field have led to the introduction of esketamine—the S-enantiomer of ketamine—administered as a nasal spray under the brand name *Spravato*, which was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of adults with treatment-resistant depression (FDA, 2019). Studies have shown that esketamine, when administered in conjunction with oral antidepressants, significantly reduces depressive symptoms and shortens time to therapeutic response. Esketamine may cause dissociative side effects such as derealization, depersonalization, illusions, and altered time perception. These symptoms are usually mild and transient, subsiding within the day of administration. Other reported side effects include transient increases in blood pressure, sedation, drowsiness, and urinary tract symptoms (Popova et al., 2019).

In parallel, the field of psychedelic-assisted therapy has gained increasing attention. Of particular interest is psilocybin, a naturally occurring hallucinogenic alkaloid found in *Psilocybe* mushrooms. Studies conducted at institutions such as Johns Hopkins University and Imperial College London suggest that one or several doses of psilocybin administered in controlled clinical settings, combined with supportive psychotherapy, can lead to a profound reduction in depressive symptoms, enhanced neuroplasticity, and improved emotional and cognitive functioning (Carhart-Harris et al., 2016; Davis et al., 2021).

The mechanism of action of psychedelics is not limited to neurochemical modulation of the serotonergic system but appears to rely—perhaps primarily—on inducing transformative existential experiences that enhance a sense of meaning, belonging, and inner coherence (Griffiths et al., 2016). Despite promising outcomes, widespread implementation of these interventions remains constrained by the need to develop standardized therapeutic protocols, provide specialized training for therapists, and address the legal and regulatory frameworks concerning the safety and legality of these substances.

3. Humanistic and Integrative Therapies

Humanistic psychotherapeutic approaches—such as Gestalt therapy, existential therapy, and person-centered therapy—serve as a valuable complement to classical cognitive-behavioral and biological models in the treatment of depression. Unlike approaches primarily focused on symptom reduction, humanistic therapies emphasize the wholeness of personal experience, prioritizing autonomy, subjectivity, emotional awareness, and the therapeutic relationship as a central healing factor (Cain, 2010; Schneider & Krug, 2017).

Gestalt therapy, in particular, fosters awareness by deepening contact with one's body, emotions, and lived experience in the present moment. Through work with "unfinished business" and the phenomenology of the here and now, clients gain access to blocked emotions and are able to reorganize their meanings and behavioral patterns (Perls et al., 1951; Francesetti, 2013). Gestalt therapy also integrates somatic and movement-based techniques, making it especially useful in treating depression with psychosomatic characteristics or rooted in complex relational histories.

Clinical and observational studies indicate that humanistic approaches are particularly effective for patients experiencing existential forms of depression—marked by a loss of meaning, a sense of emptiness, or identity crises (Cooper, 2009; Elliott et al., 2013). Within the framework of integrated psychiatry, these methods are increasingly combined with more structured interventions—such as CBT, antidepressant medication, or mindfulness-based techniques—to form personalized and multidimensional treatment plans (Norcross & Goldfried, 2019).

Modern integrative models, including relational approaches and pluralistic integration, are gaining prominence as strategies that respond to the complexity of contemporary depressive disorders, which often transcend the boundaries of single therapeutic schools (Miller et al., 2017).

4. Lifestyle Medicine and Mental Health Prevention

Contemporary clinical and epidemiological research increasingly emphasizes the role of lifestyle-related factors in both the primary prevention of depression and as supportive components of therapeutic interventions. Regular physical activity, anti-inflammatory dietary patterns (e.g., Mediterranean diet), proper sleep hygiene, and mindfulness-based interventions have demonstrated significant efficacy in reducing depressive symptom severity and lowering relapse risk (Schuch et al., 2016; Firth et al., 2019; Jacka et al., 2017).

For instance, a meta-analysis conducted by Schuch et al. (2016), which included 25 controlled trials, found that both aerobic and resistance exercises led to moderate but clinically meaningful reductions in depressive symptoms. Similarly, in a randomized controlled trial (RCT), Jacka et al. (2017) documented that adopting a Mediterranean diet among individuals with moderate to severe depression resulted in a significant improvement in mood compared to a control group.

Sleep is also gaining recognition as a crucial determinant of mental health. Disruptions in circadian rhythms and chronic sleep deprivation are strongly associated with depressive symptoms, while their normalization has been shown to significantly improve treatment outcomes (Alfonsi et al., 2020).

In this context, psychoeducational interventions play a critical role in enhancing patients' self-awareness and strengthening their sense of agency in managing their own mental well-being. Approaches such as Behavioral Activation Therapy (BAT) are based on the premise that avoidance and withdrawal from daily activities exacerbate depressive symptoms. BAT encourages individuals to re-engage in behaviors that provide positive reinforcement, thereby promoting mood enhancement and psychosocial functioning (Dimidjian et al., 2011).

Integrated psychiatric models increasingly incorporate these lifestyle-based interventions as complementary elements to pharmacotherapy and psychotherapy—forming comprehensive, multidimensional strategies for treating depression.

5. Systemic Integration and Community-Based Mental Health

Integrated psychiatry is not only a clinical concept but also a systemic one. It necessitates improved collaboration among psychiatrists, psychotherapists, primary care physicians, social workers, and community organizations. Models such as the Collaborative Care Model and stepped-care approaches have been successfully implemented across various healthcare systems to enhance coordination and efficiency of mental health services.

Digital platforms can facilitate this integration by providing shared electronic medical records, real-time communication, and centralized case management systems. Community-based mental health initiatives—such as peer support networks and school-based programs—play a crucial role in early intervention and reducing stigma associated with mental illness.

Ethical considerations, including equitable access, informed consent, and cultural competence, must guide the development and implementation of integrated care strategies. Furthermore, the growing influence of digital and psychedelic therapies underscores the need for robust oversight, continuous monitoring, and ongoing professional education to ensure safety, effectiveness, and ethical standards in evolving treatment paradigms.

CONCLUSION

The evolution of therapeutic approaches to treating depression clearly points to an increasing need for the implementation of a pluralistic and integrated model that reflects the multidimensional and complex nature of human psychological experience. The convergence of empirical evidence from biomedical sciences, a deep understanding of the relational and existential aspects of psychological suffering, and the role of lifestyle- and community-based interventions is giving rise to a new paradigm of psychiatric care: integrated psychiatry.

In this context, humanistic therapies—particularly Gestalt therapy—emerge as a valuable complement to contemporary treatment models, offering a unique approach to working with patients whose experiences may not be fully addressed by pharmacological or technological frameworks. The emphasis of these therapies on authentic contact, awareness, and the search for meaning and identity adds a vital dimension to medical procedures, enabling a more comprehensive response to the psychopathology of depression.

An integrated approach does not imply the abandonment of scientific rigor, but rather advocates for synergy across biological, psychological, social, and existential levels of intervention. Only such a holistic perspective—combining evidence-based effectiveness with empathic understanding—can offer meaningful and lasting support to individuals struggling with depression in the face of contemporary challenges. The findings and insights presented in this article serve as

a starting point for future empirical research on the effectiveness and practical implementation of integrated psychiatric care models in clinical settings.

REFERENCES

1. Alfonsi, V., Scarpelli, S., D'Atri, A., Stella, G., & De Gennaro, L. (2020). Later school start time: The impact of sleep on academic performance and health in the adolescent population. *International Journal of Environmental Research and Public Health*, 17(7), 2574. https://doi.org/10.3390/ijerph17072574

2. American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.

3. Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C., ... & Newby, J. M. (2018). Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. *Journal of Anxiety Disorders*, 55, 70–78. https://doi.org/10.1016/j.janxdis.2018.01.001

4. Baumel, A., Muench, F., Edan, S., & Kane, J. M. (2019). Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis. *Journal of Medical Internet Research*, 21(9), e14567. https://doi.org/10.2196/14567

5. Cain, D. J. (2010). *Person-Centered Psychotherapies*. Washington, DC: American Psychological Association.

6. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry*, 3(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7

7. Carlbring, P., Andersson, G., Cuijpers, P., Riper, H., & Hedman-Lagerlöf, E. (2018). Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: An updated systematic review and meta-analysis. *Cognitive Behaviour Therapy*, 47(1), 1–18. https://doi.org/10.1080/16506073.2017.1401115

8. Cooper, M. (2009). Existential therapies: Contributions to a pluralistic practice. *Journal of Contemporary Psychotherapy*, 39(2), 103–115. https://doi.org/10.1007/s10879-008-9109-6

9. Cuijpers, P., Karyotaki, E., Reijnders, M., &Purgato, M. (2020). Meta-analyses and mega-analyses of the effectiveness of digital health interventions for mental health. *World Psychiatry*, 19(3), 337–338. https://doi.org/10.1002/wps.20784

10. Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., ... &Drevets, W. C. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment

for relapse prevention in patients with treatment-resistant depression. *JAMA Psychiatry*, 76(9), 893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189

11. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. *JAMA Psychiatry*, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285

12. Dimidjian, S., Barrera, M., Martell, C., Muñoz, R. F., &Lewinsohn, P. M. (2011). The origins and current status of behavioral activation treatments for depression. *Annual Review of Clinical Psychology*, 7, 1–38. https://doi.org/10.1146/annurev-clinpsy-032210-104535

13. Elliott, R., Watson, J., Greenberg, L. S., Timulak, L., & Freire, E. (2013). Research on humanistic–experiential psychotherapies. In M. J. Lambert (Ed.), *Bergin and Garfield's handbook of psychotherapy and behavior change* (6th ed., pp. 495–538). New York: Wiley.

14. Engel, G. L. (1980). The clinical application of the biopsychosocial model. *The American Journal of Psychiatry*, 137(5), 535–544. https://doi.org/10.1176/ajp.137.5.535

15. FDA. (2019). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. Retrieved from https://www.fda.gov

16. Firth, J., Solmi, M., Wootton, R. E., Vancampfort, D., Schuch, F. B., Hoare, E., ... & Stubbs, B. (2019). A meta-review of "lifestyle psychiatry": The role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. *World Psychiatry*, 18(3), 308–328. https://doi.org/10.1002/wps.20672

17. Fitzpatrick, K. K., Darcy, A., &Vierhile, M. (2017). Delivering Cognitive Behavior Therapy to Young Adults With Symptoms of Depression and Anxiety Using a Fully Automated Conversational Agent (Woebot): A Randomized Controlled Trial. *JMIR Mental Health*, 4(2), e19. https://doi.org/10.2196/mental.7785

18. Francesetti, G. (2013). *Depression and the Body in Gestalt Therapy*. Milano: FrancoAngeli.

19. Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U., & Jesse, R. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of Psychopharmacology*, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513

20. Inkster, B., Sarda, S., & Subramanian, V. (2018). An Empathy-Driven, Conversational Artificial Intelligence Agent (Wysa) for Digital Mental Well-Being: Real-World Data Evaluation Mixed-Methods Study. *JMIR mHealth and uHealth*, 6(11), e12106. https://doi.org/10.2196/12106

21. Insel, T. R. (2017). Digital phenotyping: Technology for a new science of behavior. *JAMA*, 318(13), 1215–1216. https://doi.org/10.1001/jama.2017.11295

22. Jacka, F. N., O'Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., ... & Berk, M. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the "SMILES" trial). *BMC Medicine*, 15(1), 23. https://doi.org/10.1186/s12916-017-0791-y

23. Kendler, K. S. (2012). The dappled nature of causes of psychiatric illness: Replacing the organic–functional/hardware–software dichotomy with empirically based pluralism. *Molecular Psychiatry*, 17(4), 377–388. https://doi.org/10.1038/mp.2011.182

24. Miller, R. B., Wampold, B. E., &Varhely, K. (2017). The therapist factor: Implications for training and practice. *Psychotherapy*, 54(4), 369–375. https://doi.org/10.1037/pst0000121

25. Mohr, D. C., Weingardt, K. R., Reddy, M., & Schueller, S. M. (2017). Three problems with current digital mental health research... and three things we can do about it. *Psychiatric Services*, 68(5), 427–429. https://doi.org/10.1176/appi.ps.201600541

26. Norcross, J. C., & Goldfried, M. R. (2019). *Handbook of psychotherapy integration* (3rd ed.). New York: Oxford University Press.

27. Perls, F., Hefferline, R., & Goodman, P. (1951). *Gestalt Therapy: Excitement and Growth in the Human Personality*. New York: Julian Press.

28. Pincus, H. A., Pechura, C. M., Elinson, L., & Pettit, A. R. (2007). Depression in primary care: Linking clinical and systems strategies. *General Hospital Psychiatry*, 23(6), 311–318. https://doi.org/10.1016/S0163-8343(01)00157-1

29. Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., ... & Manji, H. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. *American Journal of Psychiatry*, 176(6), 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172

30. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. *American Journal of Psychiatry*, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905

31. Schuch, F. B., Vancampfort, D., Richards, J., Rosenbaum, S., Ward, P. B., & Stubbs, B. (2016). Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. *Journal of Psychiatric Research*, 77, 42–51. https://doi.org/10.1016/j.jpsychires.2016.02.023

32. Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: a systematic review. *The Lancet Psychiatry*, 5(1), 65–78. https://doi.org/10.1016/S2215-0366(17)30272-9

33. World Health Organization. (2019). *International Classification of Diseases 10th Revision (ICD-10): Classification of Mental and Behavioural Disorders*. Geneva: WHO.

34. World Health Organization. (2021). *Depression*. Retrieved from https://www.who.int/news-room/fact-sheets/detail/depression

35. World Health Organization. (2022). *ICD-11 for Mortality and Morbidity Statistics: Mental, behavioural or neurodevelopmental disorders*. Geneva: WHO.